Search
Copeptin is a surrogate marker for arginine vasopressin (AVP) release in response to hyperosmolal stimuli such as diabetic ketoacidosis (DKA). The objective of this work is to characterize kinetics of copeptin and osmolality, and their dynamic relationship during rehydration and insulin therapy in children with type 1 diabetes (T1D) and DKA.
Asymptomatic or subclinical SARS-CoV-2 infections are often unreported, which means that confirmed case counts may not accurately reflect underlying epidemic dynamics. Understanding the level of ascertainment (the ratio of confirmed symptomatic cases to the true number of symptomatic individuals) and undetected epidemic progression is crucial to informing COVID-19 response planning, including the introduction and relaxation of control measures.
The monoclonal antibody, palivizumab is licensed for use in high-risk infants to prevent severe illness caused by respiratory syncytial virus (RSV). The level of its use and compliance with current jurisdictional guidelines which were amended in 2010, is unknown.
Benzathine penicillin G (BPG) is used as first-line treatment for most forms of syphilis and as secondary prophylaxis against rheumatic heart disease (RHD). Perceptions that poor quality of BPG is linked to reported adverse effects and therapeutic failure may impact syphilis and RHD control programs. Clinical networks and web-based advertising were used to obtain vials of BPG from a wide range of countries.
Philanthropist and early childhood advocate Nicola Forrest has been recognised for her tirelesss commitment to the sector through being awarded an Officer of the Order of Australia.
The first major national study into the cost of providing late intervention services to children and young people has called for smarter and wiser expenditure to ensure children receive vital support services at a much earlier stage.
The nuanced message conveys the foundational importance of child development in the early years but avoids triggering concerns there are no opportunities to intervene at a later age.
Discover the EYI Research Profile at The Kids' Institute, showcasing innovative child health research and its impact on young lives.
An InFocus Research Interview with Kirsten Hancock of the Human Capability Team at The Kids Research Institute Australia on multigenerational disadvantage in Australia.
we the people worked with CoLab, a partnership between The Kids and Minderoo Foundation, to investigatethe needs of local families with children aged 0to8